Lung Cancer

Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes depending on disease stage.

Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt.

In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung cancer diagnosis to present day.

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive changes in my life.

The U.S. FDA has approved a new test for patients with lung cancer to match the correct individuals with a targeted treatment called Zegfrovy.

The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA approvals and priority reviews.

I entered remission from lung cancer 5.5 years ago, but faced a tough road readjusting, with ongoing physical, mental and emotional challenges.

Datroway received accelerated FDA approval for adults with EGFR+ advanced non-small cell lung cancer after EGFR-targeted and platinum chemotherapy.

Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.

Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.

Dr. Jared Weiss explained that radiation for lung cancer may ease symptoms or aim to cure, with newer targeted forms potentially boosting immune responses.

Those of us who’ve survived our cancer treatment journeys need to be role models to those who follow us.

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.

Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.

If there is ever an annual follow up CT scan that does not cause me significant anxiety, this year will be the one.

Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung cancer.